In an experimental study [116], the p300 inhibitor but not the anti-PD-L1 antibody significantly enhanced the efficacy of HDAC inhibitors on limiting tumor progression by blocking the HDAC inhibition-induced PD-L1 expression. The gene discussed is HDAC9; the disease is neoplasm.